Pretreatment albumin–bilirubin score and serum albumin in relation to a claims-defined fluid retention outcome during clazosentan treatment in older patients with subarachnoid hemorrhage: a multicenter retrospective cohort study

Background Fluid retention is a frequent adverse event associated with clazosentan treatment in patients with subarachnoid hemorrhage (SAH). A previous single-center study suggested an association between the pretreatment albumin–bilirubin (ALBI) score and clazosentan-associated fluid retention, but the generalizability of this finding and the incremental predictive value of the ALBI score beyond serum albumin remain uncertain. This study examined the association between the pretreatment ALBI score and a claims-defined composite outcome related to fluid retention using a nationwide Diagnosis Procedure Combination database and compared the predictive performance of the ALBI score and serum albumin. Methods We conducted a retrospective cohort study using the Medical Data Vision database. Patients aged ≥ 65 years with available pretreatment serum albumin and total bilirubin measurements who received clazosentan were included. The primary outcome was a claims-defined composite of fluid retention-related diagnostic codes or intravenous loop diuretic administration during clazosentan treatment. Sequentially adjusted multivariable logistic regression models evaluated the associations of the pretreatment ALBI score and serum albumin with the composite outcome. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC) and corrected Akaike information criterion (AICc). Results Of 474 patients, 280 (59.1%) met the composite outcome definition, including 237 (84.6%) identified by intravenous loop diuretic administration alone. The ALBI score showed small, nearly unchanged effect estimates across five sequentially adjusted models (adjusted odds ratio [OR], 1.03–1.04 per 0.1-point increase), although statistical significance varied with covariate adjustment. Serum albumin showed similarly small estimates (adjusted OR, 1.02–1.03 per 0.1-g/dL decrease). In the fully adjusted models, neither the ALBI score (adjusted OR, 1.03; 95% confidence interval [CI], 0.989–1.08; p = 0.144) nor serum albumin (adjusted OR, 1.02; 95% CI, 0.986–1.06; p = 0.212) was significantly associated with the composite outcome. Conclusion Neither the pretreatment ALBI score nor serum albumin was significantly associated with the claims-defined composite outcome in fully adjusted models among older patients with SAH receiving clazosentan. Both markers showed limited incremental predictive value, and their clinical utility for individual risk prediction remains unestablished.

Authors

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2026-11-21
DOI
https://doi.org/10.1186/s40780-026-00652-5
Primary Topic
Intracranial Aneurysms: Treatment and Complications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pretreatment albumin–bilirubin score and serum albumin in relation to a claims-defined fluid retention outcome during clazosentan treatment in older patients with subarachnoid hemorrhage: a multicenter retrospective cohort study

Yuki Nakano, Rintaro Sogawa, Hideyuki Terazono, Chisato Shimanoe et al.
Journal of Pharmaceutical Health Care and Sciences
Intracranial Aneurysms: Treatment and Complications
article

Pretreatment albumin–bilirubin score and serum albumin in relation to a claims-defined fluid retention outcome during clazosentan treatment in older patients with subarachnoid hemorrhage: a multicenter retrospective cohort study

Yuki Nakano, Rintaro Sogawa, Hideyuki Terazono, Chisato Shimanoe, Shuko Tobita, Kinuka Oguni, Atsushi Ogata, Tatsuya Abe
article en

Abstract

Background Fluid retention is a frequent adverse event associated with clazosentan treatment in patients with subarachnoid hemorrhage (SAH). A previous single-center study suggested an association between the pretreatment albumin–bilirubin (ALBI) score and clazosentan-associated fluid retention, but the generalizability of this finding and the incremental predictive value of the ALBI score beyond serum albumin remain uncertain. This study examined the association between the pretreatment ALBI score and a claims-defined composite outcome related to fluid retention using a nationwide Diagnosis Procedure Combination database and compared the predictive performance of the ALBI score and serum albumin. Methods We conducted a retrospective cohort study using the Medical Data Vision database. Patients aged ≥ 65 years with available pretreatment serum albumin and total bilirubin measurements who received clazosentan were included. The primary outcome was a claims-defined composite of fluid retention-related diagnostic codes or intravenous loop diuretic administration during clazosentan treatment. Sequentially adjusted multivariable logistic regression models evaluated the associations of the pretreatment ALBI score and serum albumin with the composite outcome. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC) and corrected Akaike information criterion (AICc). Results Of 474 patients, 280 (59.1%) met the composite outcome definition, including 237 (84.6%) identified by intravenous loop diuretic administration alone. The ALBI score showed small, nearly unchanged effect estimates across five sequentially adjusted models (adjusted odds ratio [OR], 1.03–1.04 per 0.1-point increase), although statistical significance varied with covariate adjustment. Serum albumin showed similarly small estimates (adjusted OR, 1.02–1.03 per 0.1-g/dL decrease). In the fully adjusted models, neither the ALBI score (adjusted OR, 1.03; 95% confidence interval [CI], 0.989–1.08; p = 0.144) nor serum albumin (adjusted OR, 1.02; 95% CI, 0.986–1.06; p = 0.212) was significantly associated with the composite outcome. Conclusion Neither the pretreatment ALBI score nor serum albumin was significantly associated with the claims-defined composite outcome in fully adjusted models among older patients with SAH receiving clazosentan. Both markers showed limited incremental predictive value, and their clinical utility for individual risk prediction remains unestablished.

Journal of Pharmaceutical Health Care and Sciences
Intracranial Aneurysms: Treatment and Complications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Pretreatment albumin–bilirubin score and serum albumin in relation to a claims-defined fluid retention outcome during clazosentan treatment in older patients with subarachnoid hemorrhage: a multicenter retrospective cohort study — Yuki Nakano, Rintaro Sogawa, et al. · Journal of Pharmaceutical Health Care and Sciences (2026) | TGRS Research Map | TGRS